Related Experiment Video
Updated: Sep 24, 2025

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
PLK2 targets GSK3β to protect against cisplatin-induced acute kidney injury
Xiaona Wei1, Jianping Wu1, Jiajia Li1
1Department of Nephrology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Abstract:
Cisplatin-induced acute kidney injury (AKI), which is accompanied by a rapid decline in renal function and a high risk of death, is a complex critical illness with no effective or specific treatment. Polo-like kinase 2 (PLK2), a serine/threonine kinase, is involved in the progression of multiple diseases, including cancers, cardiac fibrosis, diabetic nephropathy, etc. Here, by integrating two Gene Expression Omnibus (GEO) datasets of cisplatin-induced AKI animal models, we identified PLK2 as a significantly up-regulated gene in AKI renal tissues, which was then verified in different AKI animal models and cell models. Suppressing PLK2 using siRNAs or inhibitors could enhance cisplatin-induced AKI by inducing severe apoptosis and oxidative stress damage, while enforced PLK2 expression could prevent renal dysfunction induced by cisplatin. We further discovered that PLK2 might phosphorylate glycogen synthase kinase 3β (GSK3β) in the pathogenesis of AKI. In conclusion, our results show that PLK2 play a protective role in cisplatin-induced AKI and may be a new protective target of cisplatin nephrotoxicity.
Insights
Polo-like kinase 2 (PLK2) protects against cisplatin-induced acute kidney injury (AKI) by reducing apoptosis and oxidative stress. Upregulated PLK2 may serve as a novel therapeutic target for preventing cisplatin nephrotoxicity.
Area of Science:
- Nephrology
- Molecular Biology
- Biochemistry
Background:
- Cisplatin-induced acute kidney injury (AKI) is a severe condition lacking effective treatments.
- Polo-like kinase 2 (PLK2) is implicated in various disease processes.
- Identifying novel therapeutic targets for AKI is crucial.
Purpose of the Study:
- To investigate the role of PLK2 in cisplatin-induced AKI.
- To determine if PLK2 could be a potential therapeutic target for cisplatin nephrotoxicity.
Main Methods:
- Integrated two Gene Expression Omnibus (GEO) datasets for cisplatin-induced AKI models.
- Verified PLK2 expression in AKI animal and cell models.
- Utilized siRNAs and inhibitors to suppress PLK2; enforced PLK2 expression.
- Investigated PLK2's potential phosphorylation of glycogen synthase kinase 3β (GSK3β).
Main Results:
- PLK2 was significantly upregulated in AKI renal tissues.
- PLK2 suppression exacerbated cisplatin-induced AKI, increasing apoptosis and oxidative stress.
- Enforced PLK2 expression protected against cisplatin-induced renal dysfunction.
- PLK2 potentially phosphorylates GSK3β in AKI pathogenesis.
Conclusions:
- PLK2 plays a protective role in cisplatin-induced AKI.
- PLK2 represents a potential therapeutic target for mitigating cisplatin nephrotoxicity.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
The JAK-STAT Signaling Pathway
Acute Kidney Injury II: Pathophysiology
Cytoskeletal Linker Proteins - Plakins

